Avidity Biosciences, Inc. RNA
NasdaqSmall CapHealthcare
13F Pro quality score
Rank #2,705 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reading the latest SEC filing…
13F Pro quality score
Rank #2,705 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
Avidity Biosciences, Inc. (RNA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RNA at 22.5/100 on a composite quality score built from its SEC filings, placing it at rank #2,705 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Avidity Biosciences, Inc. reports quarterly revenue of $3.0M, net income of $-20.2M, free cash flow of $-4.0M. Top institutional holders of RNA by reported 13-F value include Sessa Capital IM, L.P., PRICE T ROWE ASSOCIATES, BlackRock, based on the most recent SEC filings. RNA trades on the Nasdaq exchange and files with the SEC under CIK 1599901. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Avidity Biosciences, Inc. directly from SEC EDGAR.